Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × ribociclib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2 Sarcoma 1 Lymphoid 1 Head & Neck 1 Breast 1

Conditions

Breast Neoplasms 83 Neoplasm Metastasis 4 Ovarian Neoplasms 3 Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Breast Neoplasms, Male 3 Breast Diseases 3 Triple Negative Breast Neoplasms 2 Neoplasms by Site 2 Multiple Endocrine Neoplasia Type 1 2 Hereditary Sensory and Autonomic Neuropathies 2 Endometrial Neoplasms 2 Breast Cancer Metastatic 2 Venous Thromboembolism 1 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Osteitis Deformans 1 Neoplastic Cells, Circulating 1 Mesothelioma 1 Lymphoma 1 Lung Neoplasms 1 Locoregional Recurrence 1 Leukemia 1 Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 HR+HER2- Advanced Breast Cancer 1 HER2-positive Advanced Breast Cancer 1

Interventions

Cyclophosphamide 5 Radiotherapy 4 olaparib 3 Paclitaxel 3 Letrozole 3 Carboplatin 3 Blood Specimen Collection 3 palbociclib 2 exemestane 2 eribulin 2 avelumab 2 abemaciclib 2 Therapeutics 2 Polymerase Chain Reaction 2 Peripheral Blood Stem Cell Transplantation 2 Melphalan 2 Mastectomy 2 Itraconazole 2 Gemcitabine 2 Fulvestrant 2 Flow Cytometry 2 Exercise 2 Etoposide 2 Cetuximab 2 Carmustine 2 Bevacizumab 2 Anastrozole 2 thymoglobulin 1 temsirolimus 1 talazoparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06760637 2026-03-02

FourLight-3

Pfizer

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡